Table 6

β blocker heart failure trials: concomitant medication

USCP CIBIS II8-150 MERIT-HF
Diuretic958-151 9991
ACE inhibitor9596908-152
Digoxin915264
Aspirin/antiplatelet agent8-153 –418-153 46
Nitrates/direct acting vasodilators8-154 328-154 58–

  • ↵8-150 CIBIS II permitted amiodarone (which the other two trials did not)—15% received this drug;

  • ↵8-151 loop diuretic;

  • ↵8-152 96% ACE inhibitor or angiotensin II receptor antagonist;

  • ↵8-153 antiplatelet agents in CIBIS II;

  • ↵8-154 direct acting vasodilators in USCP.